|
Market Cap (17-May) $8,414,961,152 (204th) |
Close (30-Jun) $11.22 |
Volume (30-Jun) 664,557 |
Shortsold (5-May) 16,072,273 (4.76%) (53rd) |
|
52w High $31.97 |
52w Low $14.42 |
P/E 57.80 |
EPS 0.15 |
TLX released this announcement to the ASX on 8 December 2021, 8:20. The announcement is marked as price sensitive, and is 2 page(s) in length and 210.29kb in size.
You can view all announcements from TLX and see how they appear on a price chart on the announcements page.
At the date of this announcement, TLX was 0.473% short sold according to ASIC data. It was ranked the 287th most shorted stock on the ASX. It is now ranked as the 53rd most shorted stock on the ASX with 4.757% of total shares short sold as of the latest reported data (05 May 2025).
| Other Recent Announcements from TLX | |
|---|---|
| Cleansing Notice | 28 June 2023, 8:23 |
| Application for quotation of securities - TLX | 28 June 2023, 8:23 |
| Proposed issue of securities - TLX | 21 June 2023, 18:12 |
| NUCLIBER - Distribution Agreement for Illuccix in Spain | 8 December 2021, 8:20 |
| Illuccix Granted Use Authorisation in Brazil | 1 December 2021, 8:19 |
| Investor Presentation - November 2021 | 16 November 2021, 8:17 |
| Australian TGA Approves Illuccix for Prostate Cancer Imaging | 2 November 2021, 9:29 |
You must be logged in to post a reply.
Telix Pharmaceuticals 